Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How do you treat ER/PR + DCIS with no identified invasive component that has microscopic sentinel lymph node metastasis? Would you complete HER2 staining on original specimen?
DCIS with nodal metastasis in young fit patient.
Related Questions
What are your top takeaways in Radiation Oncology from SABCS 2024?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
Would you offer adjuvant chemotherapy for a pT1c triple negative invasive papillary carcinoma of breast?
When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?
Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
What are your top takeaways in Breast Cancer from ASCO 2025?
How do you approach the RxPonder data in premenopausal women with ER/PR+, HER2 negative, pN1, many of whom now qualify for CDK 4/6 inhibitors in adjuvant setting besides endocrine therapy (+/- OFS) if the RS 0-13 and 14-25?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?